Life Sciences summit

The inaugural Life Sciences International Summit (the Summit), which takes place on 11 November 2010 at Croke Park, will discuss Ireland’s potential for innovation and is expected to attract over 300 delegates including world-renowned opinion leaders, experts from pharmaceutical and fine chemicals sectors, firms producing diagnostic equipment, medical devices manufacturers and international venture capitalists.

The event is being hosted by Business & Finance Media Group and is partnered with IDA Ireland, Science Foundation Ireland and Enterprise Ireland, PwC, ByrneWallace and MSD.

Conor Walsh

The Summit will attract Former Harvard ‘Innovator of the Year’ Conor Walsh, who now lectures at the University’s School of Engineering and Applied Sciences, and Ian Quinn, founder and Chairman of Creganna-Tactx Medical. Creganna-Tactx Medical is ranked among the top 10 global providers of outsourced design and manufacturing solutions to medical device companies and is Ireland’s largest indigenous medical device company.

The event – themed Towards 2020: Harnessing the Opportunities – aims to provide an overview of the challenges facing the global life sciences sector as well as critical insights into possible developments and solutions. The Summit will showcase Ireland’s considerable achievements to date in the international life sciences arena and what the country can continue to offer international investors as a global innovation test-bed for innovation.

Stephen Simpson, Director, Life Sciences, Science Foundation Ireland commented, “This is a unique opportunity in Irish terms to access a series of speakers of international renown whose reputation for imagination and technology-based business development is peerless.”

The inaugural Life Sciences International Summit (the Summit), which takes place on 11 November 2010 at Croke Park, will discuss Ireland’s potential for innovation and is expected to attract over 300 delegates including world-renowned opinion leaders, experts from pharmaceutical and fine chemicals sectors, firms producing diagnostic equipment, medical devices manufacturers and international venture capitalists.